Page 54 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology NOTCH3 in CSVD and breast cancer

doi: 10.1007/s12282-018-00941-4 in breast cancer by exploiting transcriptomics data through
bioinformatics approaches. Bioinform Biol Insights.
17. Ferlay J, Laversanne M, Ervik M, et al. Global Cancer
Observatory: Cancer Tomorrow. Lyon, France: International 2021;15:11779322211055892.
Agency for Research on Cancer; 2020. Available from: doi: 10.1177/11779322211055892
https://gco.iarc.fr/tomorrow [Last accessed on 2024 Dec 01].
30. Gamble LA, McClelland PH, Teke ME, et al. Defining
18. Porter P. Westernizing women’s risks? Breast cancer in features of hereditary lobular breast cancer due to CDH1
lower-income countries. N Engl J Med. 2008;358:213-216. with magnetic resonance imaging and tumor characteristics.
doi: 10.1056/NEJMp0708307 NPJ Breast Cancer. 2023;9(1):77.
19. McKee MJ, Keith K, Deal AM, et al. A multidisciplinary doi: 10.1038/s41523-023-00585-4
breast cancer brain metastases clinic: The University of 31. Rainville I, Hatcher S, Rosenthal E, et al. High risk of breast
North Carolina experience. Oncologist. 2016;21(1):16-20. cancer in women with biallelic pathogenic variants in
doi: 10.1634/theoncologist.2015-0328 CHEK2. Breast Cancer Res Treat. 2020;180(2):503-509.
20. Shiovitz S, Korde LA. Genetics of breast cancer: A topic in doi: 10.1007/s10549-020-05543-3
evolution. Ann Oncol. 2015;26:1291-1299. 32. Hu ZY, Liu L, Xie N, et al. Germline PALB2 mutations in
doi: 10.1093/annonc/mdv022 cancers and its distinction from somatic PALB2 mutations
in breast cancers. Front Genet. 2020;11:829.
21. Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and
outcomes in breast cancer: Reading beyond the headlines. doi: 10.3389/fgene.2020.00829
Trends Cancer. 2020;6:98-110. 33. Fusco N, Sajjadi E, Venetis K, et al. PTEN alterations and
doi: 10.1016/j.trecan.2020.01.007 their role in cancer management: Are we making headway
on precision medicine? Genes (Basel). 2020;11(7):719.
22. Corso G, Veronesi P, Sacchini V, Galimberti V. Prognosis
and outcome in CDH1-mutant lobular breast cancer. Eur J doi: 10.3390/genes11070719
Cancer Prev. 2018;27(3):237-238. 34. Angeli D, Salvi S, Tedaldi G. Genetic predisposition to breast
doi: 10.1097/CEJ.0000000000000405 and ovarian cancers: How many and which genes to test? Int
J Mol Sci. 2020;21(3):1128.
23. Kechagioglou P, Papi RM, Provatopoulou X, et al. Tumor
suppressor PTEN in breast cancer: Heterozygosity, mutations doi: 10.3390/ijms21031128
and protein expression. Anticancer Res. 2014;34(3):1387-1400. 35. Børresen-Dale AL. TP53 and breast cancer. Hum Mutat.
24. Chen J, Lindblom A. Germline mutation screening of the 2003;21:292-300.
STK11/LKB1 gene in familial breast cancer with LOH on doi: 10.1002/humu.10174
19p. Clin Genet. 2000;57(5):394-397.
36. Leontovich AA, Jalalirad M, Salisbury JL, et al. NOTCH3
doi: 10.1034/j.1399-0004.2000.570511.x expression is linked to breast cancer seeding and distant
25. Rahman N, Seal S, Thompson D, et al. PALB2, which metastasis. Breast Cancer Res. 2018;20(1):105.
encodes a BRCA2-interacting protein, is a breast cancer doi: 10.1186/s13058-018-1020-0
susceptibility gene. Nat Genet. 2007;39(2):165-167.
37. Che Mohd Nassir CMN, Damodaran T, Yusof SR, et al.
doi: 10.1038/ng1959 Aberrant neurogliovascular unit dynamics in cerebral small
26. Stucci LS, Internò V, Tucci M, et al. The ATM gene in breast vessel disease: A rheological clue to vascular parkinsonism.
cancer: Its relevance in clinical practice. Genes (Basel). Pharmaceutics. 2021;13(8):1207.
2021;12(5):727. doi: 10.3390/pharmaceutics13081207
doi: 10.3390/genes12050727 38. Wardlaw JM, Smith C, Dichgans M. Small vessel disease:
27. Gorodetska I, Kozeretska I, Dubrovska A. BRCA genes: Mechanisms and clinical implications. Lancet Neurol.
The role in genome stability, cancer stemness and therapy 2019;18:684-696.
resistance. J Cancer. 2019;10(9):2109-2127. doi: 10.1016/S1474-4422(19)30079-1
doi: 10.7150/jca.30410 39. Smith EE. Clinical presentations and epidemiology of
28. Qu Y, Qin S, Yang Z, et al. Targeting the DNA repair pathway vascular dementia. Clin Sci (Lond). 2017;131:1059-1068.
for breast cancer therapy: Beyond the molecular subtypes. doi: 10.1042/CS20160607
Biomed Pharmacother. 2023;169:115877.
40. Prabhakaran S, Naidech AM. Ischemic brain injury
doi: 10.1016/j.biopha.2023.115877
after intracerebral hemorrhage: A critical review. Stroke.
29. Khan U, Khan MS. Prognostic value estimation of BRIP1 2012;43:2258-2263.

Volume 9 Issue 3 (2025) 46 doi: 10.36922/EJMO025150095